Ascendis Pharma A/S (ASND) vs Madrigal Pharmaceuticals (MDGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Madrigal Pharmaceuticals (MDGL) has outperformed Ascendis Pharma A/S (ASND) over the past year, gaining 11.8% versus a gain of 8.8%. Over five years, MDGL leads with a +466.0% price change compared with +42.8% for ASND. Ascendis Pharma A/S is the larger company by market cap ($14.67 billion vs $11.11 billion), about 1.3 times the size.
On valuation, Ascendis Pharma A/S trades at a lower forward P/E (20.6x vs 50.0x for Madrigal Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | MDGL |
|---|---|---|
| Share price | $223.01 | $480.80 |
| Market cap | $14.67B | $11.11B |
| 1-day change | -2.37% | -1.42% |
| YTD return | +7.11% | -16.25% |
| 1-year return | +8.84% | +11.79% |
| 5-year return | +42.77% | +466.00% |
| P/E ratio (TTM) | 17.09 | — |
| Forward P/E | 20.61 | 49.95 |
| EPS (TTM) | $13.05 | $-12.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $958.40M |
| Revenue growth (YoY) | — | +432.05% |
| Net income (latest FY) | — | $-288.28M |
| Operating margin | — | -31.31% |
| Net margin | — | -30.08% |
| 52-week high | $282.15 | $615.00 |
| 52-week low | $186.05 | $393.61 |
| Distance from 52-week high | -20.96% | -21.82% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +37.14% | +41.87% |
| Average volume | 658.78K | 289.31K |
| Shares outstanding | 65.80M | 23.10M |
| Employees | 1,189 | 915 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
ASND vs MDGL FAQ
Which is bigger, Ascendis Pharma A/S or Madrigal Pharmaceuticals?
Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $14.67B compared with $11.11B for Madrigal Pharmaceuticals (MDGL).
Which stock has performed better over the past year, ASND or MDGL?
MDGL returned +11.79% over the past 12 months, compared with +8.84% for ASND (price return, excluding dividends). Past performance does not predict future results.
Are Ascendis Pharma A/S and Madrigal Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.